Wisp announced the launch of a new Longevity and Healthy Aging category offering clinician-guided treatments designed to support women’s long-term health, according to the company. The telehealth provider introduced therapies including glutathione, NAD+ and low-dose naltrexone delivered through nasal sprays or injections.
The expansion marks Wisp’s move beyond its core reproductive and sexual health services into longevity care focused on cellular energy, immune function and biological repair, the company claims. The digital care model includes asynchronous consultations with clinicians, ongoing monitoring and personalized treatment adjustments through the platform.
Wisp operates as part of the digital health ecosystem of WELL Health Technologies, which acquired a majority stake in the company in 2021 as part of its strategy to expand telehealth and e-pharmacy services in the United States.
According to the company, the longevity initiative is intended to address gaps in women-focused aging care, particularly around hormonal changes, immune-related conditions and other health issues that can emerge during perimenopause and menopause. The program also reflects Wisp’s broader strategy to expand into preventative and lifecycle-based healthcare services.
The company said the healthy aging vertical is part of its effort to build a broader digital health ecosystem offering preventative care, diagnostics and treatment services delivered through its telehealth platform.
